Conditions: Hemorrhage
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 503
Healthy volunteers: no

Brief summary:
Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.

Detailed description:

Arms:
arm 1: idarucizumab Only 1 treatment, no placebo or comparator

Interventions: intervention 1: idarucizumab
Intervention descriptions: intervention 1: idarucizumab

Protocol document: